Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Single-center Experience
100%
Readmission
100%
Hospital Readmission
100%
Hepatorenal Syndrome
100%
COVID-19
100%
Invasive Hemodynamics
100%
Cirrhotic Patients
100%
Hemodynamic Parameters
100%
Filipino nurses
100%
Sacituzumab Govitecan
100%
Hemodialysis
100%
Patients with Cancer
100%
End-of-life Care
100%
Tubulointerstitial Nephritis
100%
Severe Acute
100%
Filling Pressure
80%
Filipino
75%
Hospitalization
66%
Kidney Function
56%
Readmission Rates
50%
SN-38
50%
Acute Kidney Injury
50%
Wedge Pressure
40%
Cardiorenal Syndrome
40%
Haemodynamic Data
40%
Diuresis
40%
Renal Function Improvement
40%
Kidney Disease
40%
Confidence Interval
33%
Coronary Artery Disease
33%
Odds Ratio
33%
TROP2
33%
Adverse Effects
33%
Religious Families
25%
Cultural Contexts
25%
Inclusive Approach
25%
Large Group
25%
United States
25%
Minority Groups
25%
Immigrants in the United States
25%
Family Finance
25%
Renal Venous Hypertension
20%
Peripheral Vasoconstriction
20%
Low Filling
20%
Kidney Perfusion
20%
Right Heart Catheterization
20%
Primary Force
20%
Single-center Retrospective Study
20%
Data Profiling
20%
Meaningful Change
20%
Medicine and Dentistry
COVID-19
100%
Hepatorenal Syndrome
100%
Hemodynamic
100%
End of Life Care
100%
Hemodialysis
100%
Interstitial Nephritis
100%
Sacituzumab Govitecan
100%
Kidney Function
96%
Acute Kidney Injury
66%
SN-38
50%
Coronary Artery Disease
40%
Cardiorenal Syndrome
40%
Diuresis
40%
Kidney Dysfunction
40%
Odds Ratio
40%
Minority Group
25%
Clinician
25%
Immigrant
25%
Diabetes Mellitus
20%
Mortality Rate
20%
Logistic Regression Analysis
20%
Musculoskeletal Disease
20%
Infection
20%
Liver Graft
20%
Vasodilatation
20%
Cardiac Catheterization
20%
Liver Cirrhosis
20%
Heart Right Atrium Pressure
20%
Creatinine
20%
Retrospective Study
20%
Kidney Perfusion
20%
Reverse Transcription Polymerase Chain Reaction
20%
Comorbidity
20%
Diuretics
20%
Sacituzumab
16%
Case Presentation
16%
Triple Negative Breast Cancer
16%
Proteinuria
16%
Furosemide
16%
Membrane Antigen
16%
Gastrointestinal Toxicity
16%
Collecting Duct
16%
Nephropathy
16%
Neoplasm
16%
DNA Strand
16%
Renal Replacement Therapy
16%
Programmed Cell Death
16%
Trophoblast
16%
Glucuronidation
16%
Topoisomerase Inhibitor
16%